Literature DB >> 2537558

Immunologic approaches to blockade of the renin-angiotensin system: a review.

J B Michel1, C Guettier, R Reade, S Sayah, P Corvol, J Ménard.   

Abstract

Several immunologic approaches to blockade of the renin-angiotensin system (RAS) have been reported, involving most of the proteins and peptides of the biochemical cascade: renin, substrate, angiotensins, and converting enzyme. None as yet has involved blockade of angiotensin II receptors. Earlier and more recent studies used passive transfer of heterologous antibodies or active immunization against RAS proteins and peptides. Passive transfers have been performed with both polyclonal antibodies and now with specific monoclonal immunoglobulins. The latter are better defined in affinity, quantity, and capacity to bind and thus inhibit the biologic activity of the antigen. Active immunization produced long-term blockade of part or all of the biologic activity of the system. The immunopathologic consequences of the use of antibodies raised against a self-antigen could be of interest in defining the predominant site of storage and secretion of the relevant protein and hence the respective roles of different tissues in the production of specific proteins in, for example, the vascular pulmonary bed for converting enzyme and renal arterial tree for renin. In all cases immunologic methods offer in vivo experimental models of short- or long-term RAS blockade that could be compared with pharmacologic methods, such as converting-enzyme inhibition, angiotensin II antagonists, and renin inhibitors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537558     DOI: 10.1016/0002-8703(89)90767-9

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

Review 1.  Success and failure of vaccines against renin-angiotensin system components.

Authors:  Morris J Brown
Journal:  Nat Rev Cardiol       Date:  2009-08-25       Impact factor: 32.419

2.  Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats.

Authors:  S M Gardiner; T R Auton; M R Downham; H L Sharp; P A Kemp; J E March; H Martin; P J Morgan; A Rushton; T Bennett; J F Glover
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

3.  Angiotensin vaccination: what is the prospect of success?

Authors:  Duncan J Campbell
Journal:  Curr Hypertens Rep       Date:  2009-02       Impact factor: 5.369

4.  Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man.

Authors:  M R Downham; T R Auton; A Rosul; H L Sharp; L Sjöström; A Rushton; J P Richards; T G K Mant; S M Gardiner; T Bennett; J F Glover
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

Review 5.  The clinical potential of renin inhibitors and angiotensin antagonists.

Authors:  R J Cody
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

Review 6.  Interventional procedures and future drug therapy for hypertension.

Authors:  Melvin D Lobo; Paul A Sobotka; Atul Pathak
Journal:  Eur Heart J       Date:  2017-04-14       Impact factor: 29.983

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.